Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure

Journal of Clinical Investigation

Volumn 113, Issue 8, 2004, Pages 1138-1148

  Hayashi, Masaaki ^a   Kim, Sung Woo ^a   Imanaka Yoshida, Kyoko ^b   Yoshida, Toshimichi ^b   Abel, E Dale ^c   Eliceiri, Brian ^d   Yang, Young ^e   Ulevitch, Richard J ^a   Lee, Jiing Dwan ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MIE UNIVERSITY   (Japan)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d LA JOLLA INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 7; MYOCYTE ENHANCER FACTOR 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLEEDING; BLOOD VESSEL PERMEABILITY; BMK1 GENE; CARDIOVASCULAR MALFORMATION; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; EMBRYO DEATH; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; GENE CONTROL; GENE DELETION; GENE DISRUPTION; GENE INDUCTION; GENE MUTATION; GENE TARGETING; HISTOPATHOLOGY; IN VITRO STUDY; LETHALITY; MOUSE; MUTANT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; TRANSGENE; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; CAPILLARY PERMEABILITY; CELL SURVIVAL; ENDOTHELIAL CELLS; FETAL DEATH; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 7; MITOGEN-ACTIVATED PROTEIN KINASES; MYOGENIC REGULATORY FACTORS; RECOMBINATION, GENETIC;

EID: 2142659374     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200419890     Document Type: Article

References (60)

1. Kato, Y., et al. 1997. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 16:7054-7066.
2. Chao, T.H., Hayashi, M., Tapping, R.I., Kato, Y., and Lee, J.D. 1999. MEKK3 directly regulates MEK5 activity as part of the big mitogen activated protein kinase 1 (BMK1) signaling pathway. J. Biol. Chem. 274:36035-36038.
3. English, J.M., Vanderbilt, C.A., Xu, S., Marcus, S., and Cobb, M.H. 1995. Isolation of MEK5 and differential expression of alternatively spliced forms. J. Biol. Chem. 270:28897-28902.
4. Zhou, G., Bao, Z.Q., and Dixon, J.E. 1995. Components of a new human protein kinase signal transduction pathway. J. Biol. Chem. 270:12665-12669.
5. Kato, Y., et al. 1998. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature. 395:713-716.
6. English, J.M., et al. 1999. Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J. Biol. Chem. 274:31588-31592.
7. Kamakura, S., Moriguchi, T., and Nishida, E. 1999. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. 274:26563-26571.
8. Liu, L., et al. 2003. ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons. Proc. Natl. Acad. Sci. U. S. A. 100:8532-8537.
9. Watson, F.L., et al. 2001. Neurotrophins use the ERK5 pathway to mediate a retrograde survival response. Nat. Neurosci. 4:981-988.
10. Dinev, D. et al. 2001. Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cells. EMBO Rep. 2:829-834.
11. Regan, C. P., et al. 2002. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc. Natl. Acad. Sci. U. S. A. 99:9248-9253.
12. Sohn, S.J., Sarvis, B.K., Cado, D., and Winoto, A. 2002. ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J. Biol. Chem. 277:43344-43351.
13. Yang, J., et al. 2000. Mekk3 is essential for early embryonic cardiovascular development. Nat. Genet. 24:309-313.
14. Lin, Q., Schwarz, J., Bucana, C., and Olson, E.N. 1997. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science. 276:1404-1407.
15. Lin, Q., et al. 1998. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development. 125:4565-4574.
16. Bi, W., Drake, C.J., and Schwarz, J.J. 1999. The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. Dev. Biol. 211:255-267.
17. Adams, R.H., et al. 2000. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol. Cell. 6:109-116.
18. Tamura, K., et al. 2000. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell. 102:221-231.
19. Kuhn, R., Schwenk, F., Aguet, M., and Rajewsky, K. 1995. Inducible gene targeting in mice. Science. 269:1427-1429.
20. Rodriguez, C.I., et al. 2000. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat. Genet. 25:139-140.
21. Meyers, E.N., Lewandoski, M., and Martin, G.R. 1998. An Fgf8 mutant allelic series generated by Cre-and Flp-mediated recombination. Nat. Genet. 18:136-141.
22. Jar, P.S., et al. 1991. Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 98:5096-5100.
23. Koni, P.A., et al. 2001. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J. Exp. Med. 193:741-754.
24. Abel, E.D., et al. 1999. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J. Clin. Invest. 104:1703-1714.
25. Lobe, C.G., et al. 1999. Z/AP, a double reporter for cre-mediated recombination. Dev. Biol. 208:281-292.
26. Camenisch, T.D., et al. 2000. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 106:349-360.
27. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:593-602.
28. Brutsaert, D.L. 2003. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol. Rev. 83:59-115.
29. Ferrata, N., et al. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:439-442.
30. Cines, D.B., et al. 1998. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 91:3527-3561.
31. Gerher, H.P., et al. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273:30336-30343.
32. Tran, J., et al. 2002. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. U. S. A. 99:4349-4354.
33. Carmelier, P., et al. 1999. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 98:147-157.
34. Okamoto, S., Krainc, D., Sherman, K., and Lipton, S.A. 2000. Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A. 97:7561-7566.
35. Suzaki, Y., et al. 2002. Hydrogen peroxide stimulates c-Src-mediated big mitogen activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: potential role in cell survival following oxidative insults. J. Biol. Chem. 277:9614-9621.
36. Molkentin, J.D., Black, B.L., Martin, J.F., and Olson, E.N. 1996. Mutational analysis of the DNA binding, dimerization, and transcriptional activation domains of MEF2C. Mol. Cell Biol. 16:2627-2636.
37. Michel, C.C., and Curry, F.E. 1999. Microvascular permeability. Physiol. Rev. 79:703-761.
38. Dvorak, H.F., Brown, L.F., Detmar, M., and Dvorak, A.M. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029-1039.
39. Feng, D., Nagy, J.A., Hipp, J., Dvorak, H.F., and Dvorak, A.M. 1996. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J. Exp. Med. 183:1981-1986.
40. Alon, T., et al. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1:1024-1028.
41. Kwak, H.J., So, J.N., Lee, S.J., Kim, I., and Koh, G.Y. 1999. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett. 448:249-253.
42. Karsan, A., et al. 1997. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2 dependent and independent mechanisms. Am. J. Pathol. 151:1775-1784.
43. Fujio, Y., and Walsh, K. 1999. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 274:16349-16354.
44. Papapetropoulos, A., et al. 2000. Angiopoietin-I inhibits endothelial cell apoptosis via the Akt/survivin pathway. J. Biol. Chem. 275:9102-9105.
45. O'Connor, D.S., et al. 2000. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 186:393-398.
46. Meredith, J.E., Jr., Fazeli, B., and Schwartz, M.A. 1993. The extracellular matrix as a cell survival factor. Mol. Biol. Cell. 4:953-961.
47. Bird, I.N., et al. 1999. Homophilic PECAM-1(CD31) interactions prevent endothelial cell apoptosis but do not support cell spreading or migration. J. Cell Sci. 112(Pt 12):1989-1997.
48. Abe, J., Kusuhara, M., Ulevitch, R.J., Berk, B.C., and Lee, J.D. 1996. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J. Biol. Chem. 271:16586-16590.
49. Abe, J., Takahashi, M., Ishida, M., Lee, J.D., and Berk, B.C. 1997. c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1. J. Biol. Chem. 272:20389-20394.
50. Johnson, F.B., Sinclair, D.A., and Guarente, L. 1999. Molecular biology of aging. Cell. 96:291-302.
51. Irani, K. 2000. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. 87:179-183.
52. Cleveland, J.L., and Kastan, M.B. 2000. Cancer. A radical approach to treatment. Nature. 407:309-311.
53. Prasad, K.N., et al. 2000. Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin. Neuropharmacol. 23:2-13.
54. Giasson, B.I., et al. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 290:985-989.
55. Kato, Y., et al. 2000. Big mitogen-activated kinase regulates multiple members of the MEF2 protein family. J. Biol. Chem. 275:18534-18540.
56. Black, B.L., and Olson, E.N. 1998. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu. Rev. Cell Dev. Biol. 14:167-196.
57. Pi, X., Yan, C., and Berk, B.C. 2004. Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ. Res. 94:362-369.
58. Nicol, R.L., et al. 2001. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 20:2757-2767.
59. Nakaoka, Y., et al. 2003. Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes. Circ. Res. 93:221-229.
60. Kacimi, R., and Gerdes, A.M. 2003. Alterations in G protein and MAP kinase signaling pathways during cardiac remodeling in hypertension and heart failure. Hypertension. 41:968-977.